Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma

Trial Profile

Investigation of the Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs S 524101 (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 28 May 2014 Planned End Date changed from 1 Dec 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
    • 09 Sep 2013 Tolerability results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 13 Aug 2013 Planned number of patients changed from 64 to 96 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top